Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 57, Issue 10, Pages 4049-4057Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm401964y
Keywords
-
Categories
Funding
- National Institutes of Health National Institute on Drug Abuse [DA07315, DA03910]
Ask authors/readers for more resources
Emerging clinical and preclinical evidence suggests that a compound displaying high affinity for mu, K, and delta opioid (MOP, KOP, and DOP) receptors and antagonist activity at each, coupled with moderate affinity and efficacy at nociceptin opioid peptide (NOP) receptors will have utility as a relapse prevention agent for multiple types of drug abuse. Members of the orvinol family of opioid ligands have the desired affinity profile but have typically displayed substantial efficacy at MOP and or KOP receptors. In this study it is shown that a phenyl ring analogue (1d) of buprenorphine displays the desired profile in vitro with high, nonselective affinity for the MOP, KOP, and DOP receptors coupled with moderate affinity for NOP receptors. In vivo, Id lacked any opioid agonist activity and was an antagonist of both the MOP receptor agonist morphine and the KOP receptor agonist ethylketocydazocine, confirming the desired opioid receptor profile in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available